Driving Biologics Innovation: How Contract Development is Shaping the Industry

The global biologics contract development market size is expected to reach USD 13.8 billion by 2030, expanding at 8.1% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. Key drivers attributed to the growth include rising adoption of advanced technologies by biologics manufacturers, MA, and clinical trials in developing nations.The market includes organizations that offer services such as the development of cell lines, upstream and downstream processes, analytical methods, and formulations. These organizations specialize in developing and manufacturing stable cell lines that are extensively used in several important applications, including drug screening, gene functional studies, and biologic production.

Growing MA and collaboration activities between biopharma companies and CDOs are yet another factor assisting in market growth allowing more financial stability and amalgamation of advanced specialized technologies. For instance, in September 2022, Lonza., collaborated with biotechnology company Touchlight to expand its product portfolio with different sources of DNA for developing mRNA. Touchlight entered into this partnership to expand its consumer base to the novel doggybone DNA (dbDNA) technology via Lonza's offerings.

Many biopharma and Pharma companies are increasingly looking to outsource their activities as it helps accelerate the workflow (speed) of the company, provide unique specialized services, decrease drug development costs, and provide expertise. These factors are expected to boost the biologics contract development industry's growth.

During the COVID-19 pandemic, most clinical trials were focused on developing new therapies for treating COVID-19. However, in the post-pandemic period, research is expected to focus on cancer owing to rising incidences. Biologics such as monoclonal antibodies have gained significant popularity in treating cancer. The high potential of biologics in treating cancer and the growing number of cancer studies are likely to support the growth of the market in the coming years.

Biologics Contract Development Market Segment Highlights

Mammalian source emerged as the largest product segment in 2022 with over 52.0% share, as the majority of research is being carried out using mammalian cell lines
Process development is expected to witness the highest CAGR over the forecast period, as many companies are opting to outsource the production of recombinant proteins and monoclonal antibodies(MABs)
North America dominated the global market in 2019. An increase in strategic acquisitions partnerships and a rise in demand for specialized testing services are likely to have a positive impact
Asia Pacific is expected to register the highest CAGR over the forecast period, owing to various amendments made by regulatory organizations to change clinical trials evaluation standards in tandem with global requirements and rising investment in the Asia Pacific region

Browse through Grand View Research's Biotechnology Industry Research Reports.

The global sequencing reagents market size was estimated at USD 8.27 billion in 2024 and is projected to grow at a CAGR of 17.8% from 2025 to 2030.
The global cell counting market size was estimated at USD 9.48 billion in 2024 and is projected to grow at a CAGR of 8.7% from 2025 to 2030.

Segments Covered in the Report

This report forecasts revenue growth at global, regional country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global biologics contract development market report based on source, service, indication, and region.

Biologics Contract Development Source Outlook (Revenue, USD Million, 2018-2030)

Microbial
Mammalian
Others

Biologics Contract Development Service Outlook (Revenue, USD Million, 2018-2030)

Cell Line Development
- Microbial
- Mammalian
- Others
Process Development
- Upstream
  - Microbial
  - Mammalian
  - Others
- Downstream
  - Impurity, isolation, identification
  - Physicochemical characterization
  - Pharmaceutical analysis
  - Others
- By Product
  - MABs
  - Recombinant proteins
  - Others